Prevention of high-dose-methotrexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation

Medical Hypotheses

Volumn 68, Issue 5, 2007, Pages 1147-1153

  Cohen, Ian J ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; METHOTREXATE;

ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL EXAMINATION; COGNITIVE DEFECT; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; IRRADIATION; MUCOSA INFLAMMATION; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID; HUMANS; METHOTREXATE; MODELS, BIOLOGICAL; NEUROTOXICITY SYNDROMES; RISK FACTORS;

EID: 33847045124     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.04.074     Document Type: Article

References (49)

1. Mahoney D.H., Shuster J.J., Nitschke R., et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy. In: A pediatric oncology group study. J Clin Oncol 16 (1998) 1712-1722
2. Rubnitz J.E., Relling M.V., Harrison P.L., et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphatic leukemia. Leukemia 12 (1998) 1176-1181
3. Surtees R., Clelland J., and Hann I. Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphatic leukemia: CSF studies. J Clin Oncol 16 (1998) 1505-1511
4. Quinn C.T., Griener J.C., Bottiglieri T., et al. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 15 (1997) 2800-2806
5. Ochs J.L. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 11 (1989) 93-105
6. Winick N.J., Bowman W.P., Kamen B.A., et al. Unexpected acute neurological toxicity in the treatment of children with acute lymphatic leukemia. J Natl Cancer Inst 84 (1992) 252-256
7. Price R.A., and Jamieson P.A. The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer 35 (1975) 306-318
8. Kaplan R.S., and Wiernik P.H. Neurotoxicity of antineoplastic drugs. Sem Oncol 9 (1982) 103-129
9. Ochs J., Mulhern R., Fairclough D., et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Clin Oncol 9 (1991) 145-151
10. Levy A.S., Meyers P., Kellick M., Gorlick R., Tong L.D., and Bertino J.R. Acute stroke-like encephalopathy associated with high-dose methotrexate impurities. J Hematol Oncol 22 (2000) 360-362
11. Waber D.P., Tarbell N.J., Kahn C.M., Gelber R.D., and Sallas S.E. The relationship of sex and treatment modalities to neuropsychologic outcome in childhood acute lymphatic leukemia. J Clin Oncol 10 (1992) 810-817
12. Abelson H.T. Methotrexate and central nervous system toxicity. Cancer Treat Rep 62 (1978) 1999-2001
13. Shapiro W.R., Allen J.C., and Horten B. Chronic methotrexate toxicity to the central nervous system. Clin Bull 10 (1980) 49-52
14. Zintl F., Malke H., Reimann M., et al. Experience with modified BFM protocols in the treatment of children with acute lymphatic leukemia (ALL) in East Germany 1981-1991. Klin Padiatr 204 (1992) 221-229
15. Patte C., Auperin A., Michon J., et al. The Societe Francaise d'Oncologie pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97 (2001) 3370-3379
16. Ackland S.P., and Schilky R.L. High-dose methotrexate: a critical reappraisal. J Clin Oncol 5 (1987) 2017-2031
17. Levitt M., Nixon P.F., Pincus J.H., and Bertino J.R. Transport characteristics of folates in cerebrospinal fluid: a study utilizing doubly labeled 5-methyltetrahydrofolate and 5-formyltetrahydrofolate. J Clin Invest 50 (1971) 1301-1308
18. Makulu D.R., Smith E.F., and Bertino J.R. Lack of dihydrofolate reductase in brain tissues of mammalian species: possible implications. J Neurochem 21 (1973) 241-245
19. Pollock R.J., and Kaufman S. Dihydrofolate is present in the brain. J Neurochem 30 (1978) 253-256
20. Cohen I.J., Boneda-Skedi E., Hoofien D., et al. The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated with high-dose methotrexate: a neuropsychological and psychological study. Ped Blood and Cancer 45 (2005) 536
21. Cohen I.J. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignancy cells in the central nervous system. J Hematol Oncol 26 (2004) 156-163
22. Meadows A.T., and Evans A.E. Effects of chemotherapy on the central nervous system: a study of parenteral methotrexate in long-term survivors of leukemia and lymphoma in childhood. Cancer 37 (1976) 1079-1085
23. Winick N., Shuster J.J., Bowman, et al. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood b-precursor acute lymphatic leukemia. J Clin Oncol 14 (1996) 2803-2811
24. Evans W.E., Crom W.R., Abromowitch M., et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia: identification of a relationship between concentration and effect. New Engl J Med 314 (1986) 471-477
25. Allen J., Rosen G., Mehta B.M., and Horten B. Leukoencephalopathy following high-dose IV methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 64 (1980) 1261-1273
26. Tomer G., Cohen I.J., Kidron D., et al. Prognostic factors in non-metastatic limb osteosarcoma: a 20-year experience of one center. Int J Oncol 15 (1999) 179-185
27. Reggev A., and Djerassi I. The safety of massive doses of methotrexate (50 g) with equimolar citrovorum factor rescue in adult patients. Cancer 61 (1988) 2423-2428
28. Bleyer W.A. New vistas for leucovorin in cancer chemotherapy. Cancer 63 (1989) 995-1007
29. Balis F.M., and Poplack D.G. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol/Oncol 11 (1989) 74-86
30. Bleyer W.A., and Poplack D.G. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Sem Oncol 12 (1985) 131-148
31. Flombaum C.D., and Meyers P.A. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol 17 (1999) 1589-1594
32. Ettinger L.J. Pharmokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 50 (1982) 444-450
33. Spiegel R.J., Cooper P.R., Blum R., Speyer J.L., McBride D., and Mangiardi J. Treatment of a massive intrathecal methotrexate overdose by ventriculolumbar perfusion. New Engl J Med 311 (1984) 386-388
34. Morikawa N., Mori T., Kamenofuchi Y., Kawashima H., Takeyama M., and Hori S. Dose-related increases in cerebrospinal fluid concentrations of methotrexate in a post-operative patient with glioblastoma. Ann Pharmacother 33 (1999) 952-956
35. McAllister L.D., Doolittle N.C., Guastadisegni P.E., et al. Cognitive outcome and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46 (2000) 51-61
36. Jurgens H., Janka G., Ibrahim M., Tonert C., Winkler K., and Gobel U. Prognostic significance of exposure to intermediate-dose methotrexate in children with standard risk ALL: the COALL 82/85 experience. Haematol Blood Transfusion 34 (1992) 338-342
37. Sirotnak F.M., Moccio D.M., and Dorick D.M. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 38 (1978) 345-353
38. Borsi J.D., Wesenberg F., Stokland T., and Moe P.J. How much is too much? Folinic acid rescue in children with acute lymphatic leukemia. Eur J Cancer 27 (1991) 1006-1009
39. Wolfrom C., Hartmann R., Fengler R., Bruhmuller S., Ingwersen A., and Henze G. Randomized comparison of 36-h intermediate-dose versus 4-h high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphatic leukemia. J Clin Oncol 11 (1993) 827-833
40. Browman G.P., Goodyear M.D.E., Levine M.N., Russell R., Archibald S.D., and Young J.E. Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. J Clin Oncol 8 (1990) 203-208
41. Cohen I.J. Progression of osteosarcoma after high-dose methotrexate: over-rescue with folinic acid. Pediatr Hematol Oncol 20 (2003) 1-3
42. Thyss A.T., Milano G., Etienne M.C., et al. Evidence of CSF accumulation of 6-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. Br J Cancer 59 (1989) 627-630
43. Kamen B.A., and Vietti T. Letter to the Editor. Br J Cancer 60 (1989) 799
44. Mehta B.M., Glass J.P., and Shapiro W.R. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya administration in patients with meningeal carcinomatosis. Cancer Res 43 (1983) 436-438
45. Allen J., Rosen G., Juergens H., and Mehta B. The inability of oral leucovorin to elevate CSF 5-methyltetrahydrofolate following high dose intravenous methotrexate therapy. J Neurooncol 1 (1983) 39-44
46. Sirotnak F.M., Donsbach R.C., Moccio D.M., and Dorick D.M. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model. Cancer Res 36 (1976) 4679-4686
47. Griffin T.W., Rasey J.S., and Bleyer W.A. The effect of photon irradiation on blood brain barrier permeability to methotrexate in mice. Cancer 40 (1977) 1109-1111
48. Cohen IJ, Ratzhabi R, Kaplinski C, Zaizov R. Cerebrospinal fluid levels of methotrexate following various therapeutic regimes in children with malignancies (abstract). In: Int Pediatr Oncol Conf, Rome, Italy, October 21-24, 1981.
49. Cohen I.J., Vogel R., Matz S., Weitz R., Mor C., Stern S., et al. Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with methotrexate, vincristine and BCNU protocol (DEMOB). Cancer 57 (1986) 6-11